Intranasal Composition for Nasal Obstruction Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for nasal obstruction, particularly in children, are inadequate as they either fail to effectively address congestion and inflammation or lead to adverse reactions with prolonged use, and existing nasal decongestants are not recommended for patients under twelve due to safety concerns.

Innovation Solution

A topical intranasal composition containing carboxymethylßglucan, phosphoglucan, 18α and/or β glycyrrhetic acid, and lactoferrin, which lubricates the mucosae, reduces inflammation, and prevents bacterial proliferation, combined with decongestants like essential oils, to provide a safe and effective solution for nasal obstruction.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If corticosteroid-based and sympathomimetic topical drugs are used for nasal decongestion, then decongestion effect is improved, but adverse reactions and atrophic rhinitis medicamentosa occur

Engineering Contradiction:

Improvedecongestion effectVSAvoidadverse reactions and atrophic rhinitis

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention changes the chemical composition parameters by replacing corticosteroid-based and sympathomimetic drugs with a natural composition containing carboxymethyl-β-glucan, phosphoglucan, 18α and/or β glycyrrhetic acid, and lactoferrin. This parameter change maintains decongestion efficacy while eliminating the harmful side effects associated with conventional drugs.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention uses a composite material system combining multiple natural components (carboxymethyl-β-glucan, phosphoglucan, glycyrrhetic acid, and lactoferrin) to achieve synergistic effects. This composite approach provides effective decongestion while avoiding the toxic effects of single-component pharmaceutical drugs.

Inventive Principle:

Principle #40Composite materials

2Productivity

If nasal washing with physiological solutions is performed frequently, then mechanical removal of secretions is improved, but effectiveness against congestion and inflammation is insufficient

Engineering Contradiction:

Improvemechanical removal of secretionsVSAvoideffectiveness against congestion and inflammation

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The invention merges mechanical cleaning (nasal washing) with anti-inflammatory and decongestant actions by incorporating carboxymethyl-β-glucan and phosphoglucan for lubrication, 18α and/or β glycyrrhetic acid for anti-inflammatory effects, and lactoferrin for bacterial opposition. This combination addresses both secretions removal and underlying congestion/inflammation simultaneously.

Inventive Principle:

Principle #5Merging (Combining)

3Reliability

If conventional decongestants are used in patients under twelve, then decongestion is achieved, but safety concerns and adverse reactions increase

Engineering Contradiction:

Improvedecongestion effectVSAvoidsafety concerns and adverse reactions in children

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention uses naturally occurring, biodegradable components (carboxymethyl-β-glucan, phosphoglucan, glycyrrhetic acid, and lactoferrin) that are safe for children. These natural substances are metabolized and eliminated without accumulation, providing safety for pediatric use while maintaining decongestion efficacy.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively moisturizes and decongests the nasal mucosae, prevents bacterial complications, and reduces inflammation without adverse reactions, making it suitable for use in children and providing long-term relief from nasal obstruction symptoms.

Implementation Method 1

Lactoferrin is a basic protein belonging to the family of 'non-haem' ferritins, i. e., ferritins without the haem group (a polypeptide that chelates iron), which are able to bind iron with neutral or alkaline pH and release it with acidic pH.

Methodology Applied

Scientific EffectChelation:

Implementation Method 2

recent studies have proven that they exert an anti-inflammatory activity with sequestering action, binding to a pro-inflammatory protein referred to as HMGB1

Methodology Applied

Scientific EffectProtein binding:

Implementation Method 3

carboxymethylßglucan and/or phosphoglucan are/is able to lubricate and immuno-balance the mucosae, improving the mucociliar mobility

Methodology Applied

Scientific EffectLubrication: Lubrication

Data Source

PatentEP2320870B9Topical intranasal composition usable in the case of nasal obstruction

Publication Date: 2013.03.27 D M G ITAL

AI summary

Described herein is a composition for topical nasal use containing carboxymethylßglucan and/or phosphoglucan with 18? and/or ß glycyrrhetic acid, possibly salified, and lactoferrin useful in nasal obstruction also with bacterial complications.